Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Department of Pharmacology and Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou, China.
Institute of Clinical Medicine Research, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China.
Pharmacology. 2021;106(3-4):189-201. doi: 10.1159/000510864. Epub 2021 Feb 23.
It has been reported that necrostatin-1 (Nec-1) is a specific necroptosis inhibitor that could attenuate programmed cell death induced by myocardial ischemia/reperfusion (I/R) injury. This study aimed to observe the effect and mechanism of novel Nec-1 analog (Z)-5-(3,5-dimethoxybenzyl)-2-imine-1-methylimidazolin-4-1 (DIMO) on myocardial I/R injury.
Male SD rats underwent I/R injury with or without different doses of DIMO (1, 2, or 4 mg/kg) treatment. Isolated neonatal rat cardiomyocytes were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) treatment with or without DIMO (0.1, 1, 10, or 100 μM). Myocardial infarction was measured by TTC staining. Cardiomyocyte injury was assessed by lactate dehydrogenase assay (LDH) and flow cytometry. Receptor-interacting protein 1 kinase (RIP1K) and autophagic markers were detected by co-immunoprecipitation and Western blotting analysis. Molecular docking of DIMO into the ATP binding site of RIP1K was performed using GLIDE.
DIMO at doses of 1 or 2 mg/kg improved myocardial infarct size. However, the DIMO 4 mg/kg dose was ineffective. DIMO at the dose of 0.1 μM decreased LDH leakage and the ratio of PI-positive cells followed by OGD/R treatment. I/R or OGD/R increased RIP1K expression and in its interaction with RIP3K, as well as impaired myocardial autophagic flux evidenced by an increase in LC3-II/I ratio, upregulated P62 and Beclin-1, and activated cathepsin B and L. In contrast, DIMO treatment reduced myocardial cell death and reversed the above mentioned changes in RIP1K and autophagic flux caused by I/R and OGD/R. DIMO binds to RIP1K and inhibits RIP1K expression in a homology modeling and ligand docking.
DIMO exerts cardioprotection against I/R- or OGD/R-induced injury, and its mechanisms may be associated with the reduction in RIP1K activation and restoration impaired autophagic flux.
已有报道称,坏死抑制剂-1(Nec-1)是一种特异性的坏死调节剂,可减轻心肌缺血/再灌注(I/R)损伤引起的程序性细胞死亡。本研究旨在观察新型 Nec-1 类似物(Z)-5-(3,5-二甲氧基苄基)-2-亚氨基-1-甲基咪唑啉-4-1(DIMO)对心肌 I/R 损伤的作用及机制。
雄性 SD 大鼠在给予或不给予不同剂量 DIMO(1、2 或 4mg/kg)治疗后,发生 I/R 损伤。分离的新生大鼠心肌细胞在给予或不给予 DIMO(0.1、1、10 或 100μM)的情况下进行氧葡萄糖剥夺/再氧合(OGD/R)处理。通过 TTC 染色测定心肌梗死。通过乳酸脱氢酶(LDH)测定和流式细胞术评估心肌细胞损伤。通过免疫共沉淀和 Western blot 分析检测受体相互作用蛋白激酶 1(RIP1K)和自噬标志物。使用 GLIDE 对 DIMO 进入 RIP1K 的 ATP 结合位点进行分子对接。
1 或 2mg/kg 的 DIMO 剂量可改善心肌梗死面积。然而,DIMO 4mg/kg 剂量无效。DIMO 剂量为 0.1μM 可降低 OGD/R 处理后 LDH 漏出和 PI 阳性细胞的比例。I/R 或 OGD/R 增加了 RIP1K 的表达及其与 RIP3K 的相互作用,并通过增加 LC3-II/I 比值、上调 P62 和 Beclin-1 以及激活组织蛋白酶 B 和 L 来损害心肌自噬流。相比之下,DIMO 处理可减少心肌细胞死亡,并逆转 I/R 和 OGD/R 引起的 RIP1K 和自噬流的上述变化。同源建模和配体对接显示,DIMO 与 RIP1K 结合并抑制 RIP1K 的表达。
DIMO 对 I/R 或 OGD/R 诱导的损伤具有心脏保护作用,其机制可能与降低 RIP1K 激活和恢复受损的自噬流有关。